Drugs & Targets ODAC recommends against approval of camizestrant NDA, gives a nod to sNDA for capivasertib May 01, 2026Vol.52 No.17By Jacquelyn Cobb
Drugs & Targets FDA grants priority review for Ziihera in first-line HER2+ GEA May 01, 2026Vol.52 No.17
Drugs & Targets FDA approval of IDE supplement to expand Alpha DaRT IMPACT Trial to patients with pancreatic cancer receiving gemcitabine with abraxane May 01, 2026Vol.52 No.17
Drugs & Targets Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule May 01, 2026Vol.52 No.17
Drugs & Targets FDA grants Fast Track designation for lunresertib + zedoresertib for genomic-defined platinum-resistant ovarian cancer April 24, 2026Vol.52 No.16
Drugs & Targets EU approves Ojemda as first targeted therapy in r/r pediatric low-grade glioma regardless of BRAF alteration April 24, 2026Vol.52 No.16
Drugs & Targets FDA issues draft guidance on genome editing safety standards April 17, 2026Vol.52 No.15
Drugs & Targets FDA clears first HPV self-collection kit and assay for at-home use, marking a step toward improving screening uptake April 10, 2026Vol.52 No.14
Drugs & Targets Nuvalent submits NDA to FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC April 10, 2026Vol.52 No.14
